Published in Eur Heart J on October 04, 2007
Cardiac Magnetic Resonance in Non Ischemic Cardiomyopathy | NCT03638271
Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol (2013) 2.09
Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol (2010) 1.81
New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants. Eur J Hum Genet (2013) 1.80
Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis (2013) 1.68
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67
Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol (2015) 1.66
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail (2012) 1.51
The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.32
The spectrum of epidemiology underlying sudden cardiac death. Circ Res (2015) 1.26
Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol (2012) 1.26
Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson (2012) 1.17
The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res (2009) 1.16
Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol (2012) 1.13
Genetics of inherited cardiomyopathy. Eur Heart J (2011) 1.11
Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes (2013) 1.05
Septic cardiomyopathy: hemodynamic quantification, occurrence, and prognostic implications. Clin Res Cardiol (2011) 1.04
Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol (2010) 1.04
More severe cellular phenotype in human idiopathic dilated cardiomyopathy compared to ischemic heart disease. J Muscle Res Cell Motil (2010) 1.02
Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med (2013) 1.01
Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol (2013) 1.01
Genetics and genotype-phenotype correlations in Finnish patients with dilated cardiomyopathy. Eur Heart J (2015) 1.00
Isolated left ventricular noncompaction: clinical profile and prognosis in 106 adult patients. Heart Vessels (2013) 0.99
Celiac disease and autoimmune-associated conditions. Biomed Res Int (2013) 0.99
Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic factors. Nat Rev Cardiol (2017) 0.98
Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ Cardiovasc Genet (2014) 0.98
Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J (2012) 0.98
Forgotten cardiovascular diseases in Africa. Clin Res Cardiol (2009) 0.97
Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol (2010) 0.96
Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound (2010) 0.96
Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart (2014) 0.94
Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy. Appl Clin Genet (2014) 0.94
Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart J (2013) 0.94
Risk of idiopathic dilated cardiomyopathy in 29 000 patients with celiac disease. J Am Heart Assoc (2012) 0.93
Epidemiology and aetiology of heart failure. Nat Rev Cardiol (2016) 0.93
The role of cardiac magnetic resonance imaging in differentiating the underlying causes of left ventricular hypertrophy. Neth Heart J (2010) 0.93
Value of cardiovascular MR in diagnosing left ventricular non-compaction cardiomyopathy and in discriminating between other cardiomyopathies. Eur Radiol (2012) 0.92
Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J (2010) 0.92
Repair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy. Mol Ther Nucleic Acids (2013) 0.92
Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts. J Mol Cell Cardiol (2014) 0.92
Pregnancy in women with hypertrophic cardiomyopathy. Neth Heart J (2013) 0.89
SNP rs3825214 in TBX5 is associated with lone atrial fibrillation in Chinese Han population. PLoS One (2013) 0.88
Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med (2017) 0.87
Cardiomyopathies and myocardial disorders in Africa: present status and the way forward. Cardiovasc J Afr (2013) 0.87
The role of echocardiographic deformation imaging in hypertrophic myopathies. Nat Rev Cardiol (2010) 0.87
The BAG3 gene variants in Polish patients with dilated cardiomyopathy: four novel mutations and a genotype-phenotype correlation. J Transl Med (2014) 0.86
Obtaining insurance after DNA diagnostics: a survey among hypertrophic cardiomyopathy mutation carriers. Eur J Hum Genet (2009) 0.86
Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy. BMC Med Genet (2010) 0.86
Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol (2014) 0.85
Baseline tissue Doppler imaging-derived echocardiographic parameters and left ventricle reverse remodelling following cardiac resynchronization therapy introduction. Arch Med Sci (2011) 0.85
Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. Curr Cardiol Rev (2014) 0.85
The 12-lead ECG in peripartum cardiomyopathy. Cardiovasc J Afr (2012) 0.85
Clinical interpretation of genetic variants in arrhythmogenic right ventricular cardiomyopathy. Clin Res Cardiol (2014) 0.85
Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Fail Rev (2013) 0.85
Clinical characteristics, morbidity, and prognostic value of concomitant coronary artery disease in idiopathic dilated cardiomyopathy. Clin Res Cardiol (2013) 0.84
Alcoholic cardiomyopathy. World J Cardiol (2014) 0.84
Post-mortem whole-exome sequencing (WES) with a focus on cardiac disease-associated genes in five young sudden unexplained death (SUD) cases. Int J Legal Med (2016) 0.84
Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy. Am J Med Genet A (2011) 0.84
Serum lipidomics meets cardiac magnetic resonance imaging: profiling of subjects at risk of dilated cardiomyopathy. PLoS One (2011) 0.84
Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Neth Heart J (2009) 0.84
EH-myomesin splice isoform is a novel marker for dilated cardiomyopathy. Basic Res Cardiol (2010) 0.84
Differential gene expression of cardiac ion channels in human dilated cardiomyopathy. PLoS One (2013) 0.84
The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int (2011) 0.84
FHL2 expression and variants in hypertrophic cardiomyopathy. Basic Res Cardiol (2014) 0.84
Health status in patients at risk of inherited arrhythmias and sudden unexpected death compared to the general population. BMC Med Genet (2010) 0.83
Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis (2013) 0.83
Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One (2015) 0.83
14-3-3ε plays a role in cardiac ventricular compaction by regulating the cardiomyocyte cell cycle. Mol Cell Biol (2012) 0.83
Cardiomyopathies: focus on cardiovascular magnetic resonance. Br J Radiol (2011) 0.83
Virus detection and semiquantitation in explanted heart tissues of idiopathic dilated cardiomyopathy adult patients by use of PCR coupled with mass spectrometry analysis. J Clin Microbiol (2013) 0.83
Naturally Occurring Biventricular Noncompaction in an Adult Domestic Cat. J Vet Intern Med (2017) 0.82
Cardiac troponin T mutations promote life-threatening arrhythmias. J Clin Invest (2008) 0.82
Cardiomyopathies: a revolution in molecular medicine and cardiac imaging. Neth Heart J (2009) 0.82
Cardiac troponin structure-function and the influence of hypertrophic cardiomyopathy associated mutations on modulation of contractility. Arch Biochem Biophys (2016) 0.82
Relationship between Myocardial Extracellular Space Expansion Estimated with Post-Contrast T1 Mapping MRI and Left Ventricular Remodeling and Neurohormonal Activation in Patients with Dilated Cardiomyopathy. Korean J Radiol (2015) 0.82
The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly. Heart Fail Rev (2012) 0.82
Evaluation of hypertrophic cardiomyopathy: new horizons for CMR? Neth Heart J (2010) 0.81
Titin mutations: the fall of Goliath. Heart Fail Rev (2015) 0.81
Revisiting definition and classification of cardiomyopathies in the era of molecular medicine. Eur Heart J (2007) 0.81
Cardiac magnetic resonance imaging in dilated cardiomyopathy in adults--towards identification of myocardial inflammation. Eur Radiol (2010) 0.81
Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J (2010) 0.81
Determinants of concentric left ventricular hypertrophy in patients with resistant hypertension: RESIST-POL study. Hypertens Res (2015) 0.81
Left ventricular non-compaction -challenges and controversies. Maedica (Buchar) (2014) 0.80
Cardiomyopathies in children. Korean J Pediatr (2013) 0.80
Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardiomyopathy. Med Microbiol Immunol (2010) 0.80
A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations. BMC Med Genet (2015) 0.80
Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev (2013) 0.80
Alterations in cell adhesion proteins and cardiomyopathy. World J Cardiol (2014) 0.80
Loss of Prox1 in striated muscle causes slow to fast skeletal muscle fiber conversion and dilated cardiomyopathy. Proc Natl Acad Sci U S A (2014) 0.80
Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci (2015) 0.80
Recurrent and founder mutations in the Netherlands: mutation p.K217del in troponin T2, causing dilated cardiomyopathy. Neth Heart J (2010) 0.80
CD4+/CD25+ T-Lymphocytes and Th1/Th2 regulation in dilated cardiomyopathy. Hippokratia (2011) 0.80
MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction. Pflugers Arch (2013) 0.80
Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol (2011) 0.80
Prediction of atrial fibrillation development and progression: Current perspectives. World J Cardiol (2016) 0.80
Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long‐term follow‐up: does real healing exist? J Am Heart Assoc (2015) 0.79
LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies. BMC Med Genet (2013) 0.79
Clinical utility gene card for: hypertrophic cardiomyopathy (type 1-14). Eur J Hum Genet (2011) 0.79
Hypertrophic cardiomyopathy and ultra-endurance running - two incompatible entities? J Cardiovasc Magn Reson (2011) 0.79
Therapeutic role of mobilized bone marrow cells in children with nonischemic dilated cardiomyopathy. ISRN Pediatr (2012) 0.79
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation (2008) 7.11
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation (2003) 5.85
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17
The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol (2013) 4.81
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med (2009) 4.54
Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol (2003) 4.36
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation (2006) 3.82
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? Eur Heart J (2007) 3.65
Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J (2006) 3.55
Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm (2004) 3.54
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol (2010) 3.50
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol (2008) 3.42
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J (2006) 3.22
Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation (2005) 3.11
Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J (2004) 3.02
Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. Eur Heart J (2004) 2.87
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 2.82
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc (2008) 2.80
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J (2005) 2.74
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers]. Rev Esp Cardiol (2006) 2.63
Gender differences in the management and clinical outcome of stable angina. Circulation (2006) 2.59
Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation (2007) 2.56
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail (2010) 2.53
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood (2004) 2.52
Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 2.49
Acute heart failure syndromes: current state and framework for future research. Circulation (2005) 2.47
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J (2011) 2.44
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J (2007) 2.42
Hypertrophic cardiomyopathy. Lancet (2004) 2.41
Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol (2004) 2.40
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J (2009) 2.37
Athlete's heart or hypertrophic cardiomyopathy? Clin Res Cardiol (2008) 2.32
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J (2002) 2.27
[Takotsubo cardiomyopathy: a consensus document]. G Ital Cardiol (Rome) (2008) 2.26
Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet (2006) 2.26
Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet (2007) 2.25
Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor. Clin Chem (2004) 2.23
Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol (2002) 2.22
The elusive link between aortic wall histology and echocardiographic anatomy in bicuspid aortic valve: implications for prophylactic surgery. Eur J Cardiothorac Surg (2011) 2.19
Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol (2002) 2.19
Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol (2002) 2.15
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol (2009) 2.15
Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J (2005) 2.11
Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol (2003) 2.10
Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation (2009) 2.10